Hans Journal of Ophthalmology, Journal Year: 2024, Volume and Issue: 13(02), P. 20 - 26
Published: Jan. 1, 2024
Language: Английский
Hans Journal of Ophthalmology, Journal Year: 2024, Volume and Issue: 13(02), P. 20 - 26
Published: Jan. 1, 2024
Language: Английский
Experimental Eye Research, Journal Year: 2025, Volume and Issue: unknown, P. 110244 - 110244
Published: Jan. 1, 2025
Language: Английский
Citations
0Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113703 - 113703
Published: April 1, 2025
Language: Английский
Citations
0Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(7), P. 837 - 837
Published: June 26, 2024
Diabetic retinopathy (DR) remains the leading cause of blindness among global working-age population. Emerging evidence underscores significance diabetic retinal neurodegeneration (DRN) as a pivotal biomarker in progression vasculopathy. Inflammation, oxidative stress, neural cell death, and reduction neurotrophic factors are key determinants pathophysiology DRN. Non-apoptotic programmed death (PCD) plays crucial role regulating stress response, inflammation, disease management. Therapeutic modalities targeting PCD have shown promising potential for mitigating In this review, we highlight recent advances identifying various types DRN, with specific emphasis on necroptosis, pyroptosis, ferroptosis, parthanatos, more recently characterized PANoptosis. addition, therapeutic agents aimed at regulation addressing DRN discussed.
Language: Английский
Citations
2Archiv der Pharmazie, Journal Year: 2024, Volume and Issue: 357(10)
Published: July 2, 2024
Necroptosis is a form of regulated necrotic cell death and has been confirmed to play pivotal roles in the pathogenesis multiple autoimmune diseases such as rheumatoid arthritis (RA) psoriasis. The development necroptosis inhibitors may offer promising therapeutic strategy for treatment these diseases. Herein, starting from in-house hit compound 1, we systematically performed structural optimization discover potent with good pharmacokinetic profiles. resulting 33 was inhibitor both human I2.1 cells (IC
Language: Английский
Citations
2Chinese Medical Journal, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 23, 2024
Abstract Background: Retinal ganglion cell (RGC) death caused by acute ocular hypertension is an important characteristic of glaucoma. Receptor-interacting protein kinase 3 (RIPK3) that mediates necroptosis a potential therapeutic target for RGC death. However, the current understanding targeting agents and mechanisms RIPK3 in treatment glaucoma remains limited. Notably, artificial intelligence (AI) technologies have significantly advanced drug discovery. This study aimed to discover inhibitor with AI assistance. Methods: An model was used simulate pathological vivo . We employed series methods, including large language graph neural network models, identify compounds RIPK3. Subsequently, these candidates were validated using molecular simulations (molecular docking, absorption, distribution, metabolism, excretion, toxicity (ADMET) prediction, dynamics simulations) biological experiments (Western blotting fluorescence staining) vitro Results: AI-driven screening techniques greatly accelerate development. A compound called HG9-91-01, identified exerted neuroprotective effects Our research indicates all five recommended able protect morphological integrity cells when exposed hypoxia glucose deficiency, HG9-91-01 showed higher survival rate compared other candidates. Furthermore, found retinal structure reduce loss layers model. It also observed highly correlated inhibition PANoptosis (apoptosis, pyroptosis, necroptosis). Finally, we can regulate key proteins related PANoptosis, indicating this exerts retina inhibiting expression apoptosis, necroptosis. Conclusion: AI‐enabled discovery revealed could serve as
Language: Английский
Citations
1Experimental Eye Research, Journal Year: 2024, Volume and Issue: unknown, P. 110228 - 110228
Published: Dec. 1, 2024
Language: Английский
Citations
1Hans Journal of Ophthalmology, Journal Year: 2024, Volume and Issue: 13(02), P. 20 - 26
Published: Jan. 1, 2024
Language: Английский
Citations
0